期刊文献+

CD4+CD25+调节性T细胞在胃癌患者外周血分布的临床意义和作用机制 被引量:2

Distribution of CD4 +CD25 + T Regulatory Cells in Peripheral Blood of Patients with Gastric Cancer
原文传递
导出
摘要 目的:探讨CD4+CD25+调节性T细胞在胃癌患者外周血分布的临床意义及其作用机制。方法流式细胞术分析不同TNM分期的胃癌患者和健康者外周血CD4+CD25+调节性T细胞的比例。免疫磁珠分离胃癌患者和健康者外周血CD4+CD25+调节性T细胞,将CD4+CD25+调节性T细胞与淋巴细胞体外共培养, CCK8方法检测CD4+CD25+调节性T细胞对淋巴细胞的增殖能力的影响。 RT-PCR检测CD4+CD25+调节性T细胞特异性转录因子Foxp3 mRNA的表达水平。结果胃癌患者外周血CD4+CD25+调节性T细胞的比例明显高于健康者,差异具有统计学意义(P<0.05)。其中Ⅲ期和Ⅳ期胃癌患者外周血调节性T细胞的比例均明显高于Ⅰ-Ⅱ期胃癌患者,差异具有统计学意义( P <0.05)。与健康者相比,胃癌患者 CD4+CD25+调节性T细胞能明显抑制淋巴细胞增殖,其差异具有统计学意义( P<0.05),而且Ⅲ期和Ⅳ期胃癌患者CD4+CD25+调节性T细胞抑制淋巴细胞增殖的能力明显强于Ⅰ-Ⅱ期胃癌患者,其差异具有统计学意义(P<0.05)。进一步分析显示胃癌患者CD4+CD25+调节性T细胞Foxp3 mRNA的表达水平均明显高于健康者,差异具有统计学意义(P<0.05)。其中Ⅲ期和Ⅳ期胃癌患者Foxp3 mRNA的表达水平明显高于Ⅰ-Ⅱ期胃癌患者,其差异具有统计学意义(P<0.05)。结论调节性T细胞可能通过增强Foxp3 mRNA表达发挥免疫抑制作用,促进胃癌的发生发展。通过监测外周血调节性T细胞有利于评估胃癌患者免疫功能和病情进展。 Objective To explore the clinical significance and mechanism of CD4 +CD25 + T regulatory cells in patients with gastric cancer. Methods The proportion of peripheral CD4 +CD25 +T regulatory cells was detected in 60 patients with gastric cancer at different TNM stages and 30 healthy subjects by flow cytometry. CD4 +CD25 + T regulatory cells were isolated from patients with gastric cancer and healthy subjects by MACS, and cultured with lymphocytes in vitro. The effect of CD4 +CD25 + T regulatory cells on the proliferation of lymphocytes was examined by CCK8 method and the expression levels of Foxp3 mRNA were measured by RT-PCR. Results The proportion of CD4 +CD25 + T regulatory cells was significantly higher in patients with gastric cancer than in health-y subjects ( P〈0. 05 ) . Furthermore, it was significantly increased in patients at stage Ⅲ and stage Ⅳ when compared with those at stageⅠ-Ⅱ ( P〈0. 05 ) . CD4 +CD25 + T regulatory cells in patients with gastric cancer could significantly inhibit the proliferation of lymphocytes when compari-son with those in healthy subjects ( P〈0. 05 ) . What ’ s more, the inhibitory effect of CD4 +CD25 + T regulatory cells on the lymphocyte growth was significantly stronger in patients at stage Ⅲand stage Ⅳ than in patients at stageⅠ-Ⅱ ( P〈0. 05 ) . The mRNA levels of Foxp3 were signifi-cantly higher in CD4 +CD25 + T regulatory cells in patients with gastric cancer than those in healthy subjects ( P〈0. 05 ) . It was significantly increased in patients at stageⅢand stageⅣwhen com-pared with those at stageⅠ-Ⅱ ( P〈0. 05 ) . Conclusion T regulatory cells may inhibit the im-mune response by up-regulating the Foxp3 expression and promote the development of gastric canc-er. Monitoring T regulatory cells will help to evaluate the immune function of patients with gastric cancer and the development of the disease.
作者 谢燕 杨秀红
出处 《医学分子生物学杂志》 CAS 2016年第3期168-172,共5页 Journal of Medical Molecular Biology
关键词 调节性T细胞 胃癌 机制 T regulatory cells gastric cancer mechanism
  • 相关文献

参考文献9

  • 1FERLAY J, SHIN H R, BRAY F, et al. Estimates ofworldwide burden of cancer in 2008 : GLOBOCAN 2008[J].Int J Cancer,2010,127(12) :2893-2917.
  • 2DESANTIS C E,LIN C C,MARIOTTO A B,et al. Cancertreatment and statistics 2014 [ J ]. CA Cancer J Clin,2014,64(4) :252-271.
  • 3KLEIN E,NAGY N,RASUL E. Modification of cell differ-entiation ,one of the mechanisms in thesurveillance of ma-lignancy [J] .Cancer Immunol Res ,2015 ,3(2) ;97-102.
  • 4SASADA T, KIMURA M,YOSHIDA Y,et al. CD4 +CD25 + regulatory T cells in patients with gastrointestinalmalignancies : possible involvement of regulatory T cells indisease progression [ J ] . Cancer, 2003 , 98 ( 5 ) : 1089-.
  • 5WHITESIDE T L. What are regulatory T cells ( Treg) regu-lating in cancer and why? [ J]. Semin Cancer Biol,2012,22(4) :327-334.
  • 6阎永贞,那可,魏晓东,金媛媛,赵波,赵文杰.肿瘤免疫逃逸机制的研究进展[J].复旦学报(医学版),2013,40(5):619-624. 被引量:44
  • 7WOLF A M, WOLF D, STEURER M, et al. Increase ofregulatory T cells in the peripheral blood of cancer pa-tients [J]. Clin Cancer Res,2003 ,9(2) ;606-612.
  • 8林泽伟,骆必伟,袁晓东,田佩凯,谢勇,欧希,刘晓平,刘吉奎.原发性肝癌患者肿瘤浸润T淋巴细胞亚群分析[J].中国现代普通外科进展,2013,16(7):523-526. 被引量:12
  • 9姜艳丽,刘磊,王雪野,刘龑航.外周血CD4^+CD25^+CD127^(low)调节性T细胞在恶性肿瘤患者免疫功能评估中的作用[J].中国实验诊断学,2015,19(7):1117-1120. 被引量:13

二级参考文献57

  • 1张晶,谢幸,叶大风.黏附分子与肿瘤免疫逃逸[J].实用肿瘤杂志,2004,19(5):449-452. 被引量:18
  • 2Wada Y, Nakashima O, Kutami R, et al. Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration[J]. Hepa- tology, 1998,27(2):407-414.
  • 3Mosmann TR, Cherwinski H, Bond MW, et aL Two types of murine helper T cell clone I definition according to profiles files of lym- phokine activities and secreted proteins [J]. hnmunol, 1986,136 (7): 2348-2357.
  • 4Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-pro- ducing CD4+ effector T ceils develop via a lineage distinct from the T helper type 1 and2 lineages [J]. Nat Immunol, 2005,6( 11 ):1123-1132.
  • 5Dunn GP, Old 13. Schreiber RD. The three Es of cancer immu- noediting[J]. Annu Rev hnnmnol, 2004,22:329-360.
  • 6Johansson M, Denardo DG, Coussens LM. Polarized immune re- sponses differentially regulate cancer development[,J], lmmunol Rev, 2008.222:145-154.
  • 7Kemp RA, Ronchese F. Tumor-specific Tel. hut not To2, cells de- liver protective antitumtw imnmnity [J]. Immunol, 2001.167(11): 6497-6502.
  • 8Pang YL, Zhang HG, Peng JR, et al. The inmtunosuppressive tumor mic'roen-vironnemt in hepalocellular carcinoma[J]. Cancer Imnmnol hnmunother. 2009,58 (6):877-886.
  • 9Hiroishi K, Eguchi J, Baba T, et al. Inmwari M. Strong CDS(+) T- cell respnnses against tumor-associated antigens prolong the recur- rence-free interval 'after tumor treatment in patients with hepato- cellular carcinoma[J]. J Gastroenterol, 2010,45(4):451-458.
  • 10Zhang HH, Mei MH, Fei R, et al. Regulatory T eell depletion en- hances tumor specific CD8 T-cell responses, elicited by tumor antigen NY-ESO-lb in hepatoeellular carcinoma patients, in vitro [J]. Int J Oncol, 2010,36(4):841-848.

共引文献63

同被引文献25

引证文献2

二级引证文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部